Imedex® is an industry leader in providing certified, independent continuing medical education to health care professionals.

April 13-14, 2018

New York, New York

Scientific Agenda

 

Friday, April 13, 2018

Session I: Plasma Cell Disorders

Session Chair: Robert Z. Orlowski, MD, PhD

8:00 am

Introduction and pre-activity audience survey

8:10 am

Novel small molecules in multiple myeloma

8:30 am

Induction therapy for myeloma should be adapted to molecular risk

8:50 am

One size fits all for induction therapy in myeloma

9:10 am

Novel immunotherapies and chimeric antigen receptor t-cells for myeloma

9:30 am

Three drug regimens should be standard for myeloma salvage therapy

9:50 am

Four drug regimens should be standard for myeloma salvage therapy

10:10 am

Final remarks and post-activity audience survey

10:20 am

Break

Session II: Chronic Myeloid Leukemia

Session Chair: David P. Steensma, MD

10:40 am

Introduction and pre-activity audience survey

10:50 am

When can TKIs be stopped in CP-CML?

11:10 am

CML and pregnancy: patient and partner considerations

11:30 am

Options for the patient with CML for whom all TKIs have “failed”

11:50 am

Final remarks and post-activity audience survey

12:00 pm

Lunch – Ancillary Events

Session III: Chronic Lymphocytic Leukemia

Session Chair: David P. Steensma, MD

1:30 pm

Introduction and pre-activity audience survey

1:40 pm

Debate: Will novel-agent based combination therapy become standard of care for CLL?
Yes: Developing time-limited novel-agent based combination therapies should be our goal
No: The best way to use novel agents in CLL to maximize duration of response is by giving them sequentially as monotherapies

2:10 pm

What to do after BTKi therapy fails

2:30 pm

Monoclonal B cell lymphocytosis: are there patients who need close follow-up?

2:50 pm

Final remarks and post-activity audience survey

3:00 pm

Break

Session IV: Acute Leukemias

Session Chair: David P. Steensma, MD

3:20 pm

Introduction and pre-activity audience survey

3:30 pm

New drugs for AML

3:50 pm

Current AML landscape: Where do we stand in 2018?

4:10 pm

Debate: Clinical Scenarios in AML: traditional vs targeted therapy

4:40 pm

Final remarks and post-activity audience survey

4:50 pm

Break

 

Saturday, April 14, 2018

Session V: Not-So-Benign Hematology

Session Chair: David P. Steensma, MD

8:15 am

Welcome and pre-activity audience survey

8:25 am

New therapies for sickle cell disease

8:45 am

New approaches to hemophilia

9:05 am

New treatments for thalassemia

9:25 am

Final remarks and post-activity audience survey

9:35 am

Break

Session VI: MPNs and MDS

Session Chair: David P. Steensma, MD

9:55 am

Welcome and pre-activity audience survey

10:05 am

Evaluating and Managing “Triple Negative” MPN

10:25 am

Novel therapies and combinations for MDS

10:45 am

How should IPSS-R Intermediate Risk MDS be approached?
For Most Patients, Like Higher-risk MDS
For Most Patients, Like Lower-risk MDS

11:15 am

New drugs for MPN

11:35 am

Final remarks and post-activity audience survey

11:45 am

Lunch

Session VII: Lymphomas

Session Chair: John P. Leonard, MD

1:15 pm

Introduction and pre-activity audience survey

1:25 pm

Update: New approaches for the treatment of follicular lymphoma

1:45 pm

Debate: What is the best therapy for the treatment of young patient with recurrent follicular lymphoma and a short first remission?
Chemotherapy and/or novel agents
Stem cell transplant approaches

2:15 pm

Break

Session VIII: Non-Follicular Lymphomas

Session Chair: John P. Leonard, MD

2:35 pm

Update: Who should receive treatment with something beyond R-CHOP for aggressive lymphoma?

2:55 pm

Debate: CAR-T cell therapies will have a major impact on outcomes for patients with recurrent DLBCL over the next 3 years
Yes
No

3:25 pm

Update: Advance stage Hodgkin lymphoma

3:45 pm

Debate: Should brentuximab vedotin be incorporated into upfront therapy for most patients with advanced stage Hodgkin lymphoma
Pro
Con

4:15 pm

Final remarks and post-activity audience survey

4:25 pm

Adjourn